Silver Nanoparticles in Multidrug Resistant Bacteria

Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04431440

Enrollment

150

Registered

2020-06-16

Start date

2020-06-01

Completion date

2020-10-13

Last updated

2020-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multidrug Resistent Bacteria

Brief summary

Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)

Interventions

OTHERsilver nanoparticles

effect silver nanoparticles will be examined on multidrug resistant bacteria

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Intensive care patients

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
bactericidal effect of silver nanoparticles on multidrug resistant bacteria	24 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026